Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This randomized controlled trial is designed to evaluate safety, effectiveness and
pharmacokinetic-pharmacodynamic (PK/PD) relationships associated with three different
Nitazoxanide (NTZ) treatment regimens added to Tenofovir Disoproxil Fumarate (TDF), Tenofovir
Alafenamide (TAF) or Entecavir (ETV) in treating Chronic Hepatitis B (CHB).